InvestorsHub Logo
Followers 2
Posts 19
Boards Moderated 0
Alias Born 03/26/2014

Re: None

Monday, 07/21/2014 8:34:27 AM

Monday, July 21, 2014 8:34:27 AM

Post# of 506
Sinovac Biotech Selected As Sole Provider Of Hepatitis A Vaccine In Beijing Program

07:28 AM EDT, 07/21/2014 (MT Newswires) -- Sinovac Biotech (SVA) has been selected by the Beijing Health Bureau as the sole supplier of inactivated hepatitis A vaccine in pre-filled syringe dosage to the Expanded Program of Immunization (EPI) for Beijing. The tender is valued at approximately 16 million RMB.

The vaccines purchased by the Beijing Health Bureau will be used for the period from 2014 to 2016. The company expects to begin delivery in the coming months based upon demand.

Shares of SVA are at $5.60 with a 52-week range of $3.80 - $8.14.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent SVA News